Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of patients relapsed and received diverse CT producing modest benefits, and nearly all patients will die. After first line CT including platinum salt, monotherapy (doxorubicin or paclitaxel) is frequently used for relapsed patients, but the response rate (RR) is <20%, progression-free survival (PFS) <4 months, and OS <1 year. In this unmet need situation, a better knowledge of these aggressive neoplasms is essential to propose new therapeutic options.

Study Overview

• Status: Recruiting
• Conditions: Ovarian Carcinosarcoma; Endometrial Carcinosarcoma
• Intervention / Treatment: Drug: Niraparib; Combination product: Niraparib + TSR-042 (Dostarlimab); Drug: Chemotherapy Drugs

• Study Type: Interventional
• Enrollment (Estimated): 138
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Isabelle RAY-COQUARD, Professor; Phone Number: +33184852020; Email: apailhe@arcagy.org
• Study Contact Backup: Name: Bénédicte VOTAN; Phone Number: +33184852020; Email: apailhe@arcagy.org

Study Locations

• France
  • Angers, France, 49055
    • Recruiting
    • ICO Paul Papin
    • Principal Investigator: Paule AUGEREAU, MD
  • Besançon, France, 25000
    • Active, not recruiting
    • CHRU Jean Minjoz
  • Bordeaux, France, 33000
    • Recruiting
    • Centre Régional de Lutte contre le cancer - Institut Bergonié
    • Principal Investigator: Coriolan LEBRETON, MD
  • Brest, France, 29200
    • Not yet recruiting
    • CHU de BREST - Hôpital Cavale Blanche
    • Contact: Laura DEIANA, MD
  • Caen, France, 14000
    • Recruiting
    • Centre Francois Baclesse
    • Principal Investigator: Florence Joly, MD
  • Clermont-Ferrand, France, 63000
    • Recruiting
    • Centre Jean Perrin
    • Principal Investigator: Elsa KALBACHER, MD
  • Dijon, France, 21079
    • Not yet recruiting
    • Centre Georges François Leclerc
    • Principal Investigator: Jean-David FUMET, MD
  • Lille, France, 59000
    • Recruiting
    • Centre Oscar Lambret
    • Principal Investigator: Mathilde SAINT-GHISLAIN, MD
  • Limoges, France, 87042
    • Not yet recruiting
    • CHU de Limoges - Hôpital Dupuytren
    • Principal Investigator: Laurence VENAT, MD
  • Lyon, France, 69001
    • Recruiting
    • Centre Leon Berard
    • Principal Investigator: Isabelle Ray Coquard, MD
  • Marseille, France, 13000
    • Recruiting
    • Institut Paoli Calmettes
    • Principal Investigator: Magali Provansal, MD
  • Nantes, France, 44000
    • Active, not recruiting
    • Hôpital Privé du Confluent S.A.S.
  • Nîmes, France, 30900
    • Not yet recruiting
    • Centre Hospitalier Universitaire de Nîmes, Institut de Cancérologie du GARD
    • Principal Investigator: Delphine DULIEGE, MD
  • Paris, France, 75020
    • Recruiting
    • Groupe Hospitalier des Diaconesses Croix Saint-Simon
    • Principal Investigator: Antoine ANGELERGUES, MD
  • Paris, France, 76016
    • Recruiting
    • Institut Curie
    • Principal Investigator: Audrey Bellesoeur, MD
  • Poitiers, France, 86000
    • Recruiting
    • Hopital Milétrie - Centre Hospitalier Universitaire Poitiers
    • Contact: Sheik EMAMBUX
    • Principal Investigator: Sheik EMAMBUX, MD
  • Rennes, France, 35000
    • Recruiting
    • Centre Eugène Marquis
    • Principal Investigator: Claudia LEFEUVRE-PLESSE, MD
  • Saint-Herblain, France, 44800
    • Recruiting
    • ICO - Centre René Gauducheau
    • Principal Investigator: Dominique Berton, MD
  • Saint-Priest-en-Jarez, France, 42271
    • Not yet recruiting
    • CHU Saint-Etienne - Pôle de Cancérologie
    • Principal Investigator: Pauline CORBAUX, MD
  • Strasbourg, France
    • Recruiting
    • Hopitaux Universitaires de Strasbourg
    • Contact: Lauriane EBERST
  • Strasbourg, France, 67200
    • Completed
    • ICANS
  • Toulouse, France, 31000
    • Recruiting
    • IUCT Oncopole - Institut Claudius Régaud
    • Principal Investigator: Laurence Gladieff, MD
  • Vandœuvre-lès-Nancy, France, 54519
    • Not yet recruiting
    • ICL - Centre Alexis Vautrin
    • Contact: Yolanda FERNANDEZ, MD
  • Villejuif, France, 94800
    • Recruiting
    • Institut Gustave Roussy
    • Principal Investigator: Alexandra Leary, MD
• Italy
  • Bologna, Italy, 40138
    • Active, not recruiting
    • Azienda Ospedaliero-Universitaria di Bologna IRCCS Istituto di Ricerca e di Cura a Carattere Scientifico
  • Catania, Italy, 95126
    • Active, not recruiting
    • Azienda Ospedaliera Per L'Emergenza Cannizzaro
  • Meldola, Italy, 47014
    • Active, not recruiting
    • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
  • Milan, Italy, 20132
    • Active, not recruiting
    • Ospedale San Raffaele S.r.l.
  • Milan, Italy, 20159
    • Active, not recruiting
    • Humanitas Mirasole S.p.A.
  • Naples, Italy, 80131
    • Active, not recruiting
    • Irccs Istituto Nazionale Tumori Fondazione Pascale
  • Roma, Italy, 00168
    • Active, not recruiting
    • Fondazione Policlinico Universitario Agostino Gemelli Irccs
  • Torino, Italy, 10128
    • Active, not recruiting
    • Azienda Ospedaliera Ordine Mauriziano di Torino
• Spain
  • Madrid, Spain, 28034
    • Recruiting
    • Hospital Universitario Ramon y Cajal
    • Contact: Eva Maria GUERRA, Dr
  • Madrid, Spain, 28041
    • Active, not recruiting
    • Hospital Universitario 12 de Octubre
  • Murcia, Spain, 30120
    • Active, not recruiting
    • Hospital Virgen de la Arrixaca
  • Valencia, Spain, 46010
    • Active, not recruiting
    • Hospital Clinico Universitario de Valencia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Progressive or recurrent uterine carcinosarcoma (Malignant Mixed Mullerian Tumor-MMMT).
2. The primary diagnosis must be histologically confirmed by pathological expert review of the initial tumor or biopsy at relapse.
3. Mandatory tumor samples: Availability of an archival FFPE tumor sample(s) from diagnosis, or if not available from relapse setting.
4. Progressive disease as defined by RECIST 1.1.
5. Failure after ≥1 prior platinum containing regimen, which may have been given in the adjuvant setting.
6. Patient must have had 1 prior chemotherapeutic regimen for management of carcinosarcoma that may have included chemotherapy, chemotherapy and radio-chemotherapy, and/or consolidation/maintenance therapy.
7. Patient must be free of active infection requiring antibiotics.
8. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to beginning protocol treatment; continuation of hormone replacement therapy is permitted.
9. Patient must have ECOG Performance Status ≤1.
10. Life expectancy of > 2 months.

11. Adequate bone marrow function:

    • Platelet count greater than or equal to 100,000/mm3
    • Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3
    • Hemoglobin > 9g/dL

12. Adequate hepatic and renal function:

    • Total bilirubin ≤1.5x Upper Limit of Normal (ULN) unless liver metastases are present, in which case they must be ≤3x ULN (≤2.0 in patients with known Gilberts syndrome OR direct bilirubin ≤ 1 x ULN)
    • Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN unless liver metastases are present, in which case they must be ≤5x ULN
    • Alkaline phosphatase < 2.5 times ULN
    • Serum albumin > 3 g/dL
13. International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) ≤1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
14. Patient must have normal BP or adequately treated and controlled hypertension (systolic BP≤140 mmHg and/or diastolic BP ≤90 mmHg)
15. Patient receiving corticosteroids may continue as long as their dose is stable and ≤10mg/day (prednisone equivalent) for at least 4 weeks prior to initiating protocol therapy.
16. Patient must agree to not donate blood during the study or for 90 days after the last dose of study treatment.

17. Patient has a negative urine or serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 4 monhs after the last dose of study treatment, or is of nonchildbearing potential.

    • Non-childbearing potential is defined as follows:

      • ≥45 years of age and has not had menses for >1 year
      • Patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
      • Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.
    • For women of childbearing potential: the patient must be willing to use a highly effective contraception measure throughout the study, starting with the screening visit through 4 months after the last dose of study treatment. See Section 4.3. for a list of highly effective contraception methods. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
18. Patient must agree to not breastfeed during the study and for 4 months after the last dose of study treatment.
19. Patient able to take oral medications.
20. Female aged ≥18 years at time of signing ICF.
21. Patient must have signed an approved informed consent.
22. For France only: patient affiliated to, or a beneficiary of, a social security category.

Exclusion Criteria:

1. Not enrolled in any interventional clinical trial (except to biological trials that must be validated by the sponsor)
2. Prior treatment with niraparib or other PARPi therapy or PD1/PDL-1 inhibitors.
3. Patient has had investigational therapy, immunotherapy, chemotherapy or biological therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to treatment initiation. Patient has had radiotherapy within 4 weeks prior to treatment initiation.
4. Patients must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
5. Patient who has received more than 3 prior cytotoxic chemotherapies for management of uterine carcinosarcoma.
6. Patient with persistent, clinically significant > Grade 1 toxicity.
7. Patient has clinically significant cardiovascular disease (eg, significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, uncontrolled cardiac arrhythmia or unstable angina < 6 months to enrollment, NYHA grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or greater peripheral vascular disease, and history of cerebrovascular accident within 6 months)
8. Patient with any other severe concurrent disease, which may increase the risk associated with study participation or study drug administration and, in the judgment of the investigator, would make the patient inappropriate for entry into this study, including significant neurologic, psychiatric, infectious, hepatic, renal, or gastrointestinal diseases or laboratory abnormalities. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
9. Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or hydration or any other gastro-intestinal disorders or abnormalities, including difficulty swallowing, that would interfere with drug absorption.
10. Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities
11. Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks prior to Day 1 of protocol therapy or any radiation therapy within 1 week prior to Day 1 of protocol therapy.
12. Patient has a diagnosis of immunodeficiency or has received systemic steroid therapy >10mg/day (prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy

13. Participants with known HIV infection are allowed with the following requirements:

    Documented evidence of plasma HIV-1 RNA persistently <50 copies/mL ≤3 months prior to AND at Screening. In the >3 to 12 months prior to Screening, plasma HIV-1 RNA consistently <50 c/mL required; if single increases ≥50 c/mL occurred, they cannot have been persistent nor associated with antiretroviral resistance per investigator assessment AND CD4 cell count >350 cells/mm3 over past 12 months and at Screening (and no measurement ≤350 cells/mm3 during that time period) AND Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines Participants with history of CDC Stage 3 AIDS-defining disease (CDC, 2014; also known as acquired immunodeficiency syndrome - defining disease) are allowed if AIDS-defining disease has been treated and cured or is stable for ≥3 months prior to study entry. Cutaneous Kaposi's sarcoma not requiring systemic therapy is allowed.

    No history of HIV-associated non-Hodgkin lymphoma ≤5 years prior to study entry.

    No treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

14. Patient has known active hepatitis B (e. g., hepatitis B surface antigen [HBsAg] reactive and HBcAb reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).
15. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
16. Patient must not have a history of interstitial lung disease.
17. Patient has received a live vaccine within 30 days of initiating protocol therapy.
18. Patient must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy.
19. Patient must not have received colony-stimulating factors (e.g, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
20. Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
21. Symptomatic CNS metastasis or leptomeningeal carcinomatosis.
22. Patients with a history of other invasive malignancies (any evidence of other malignancy being present within the last 3 years) or with a concomitant invasive malignancy, with the exception of non-melanoma skin cancer; patients are also ineligible if their previous cancer treatment contraindicates this protocol therapy.
23. Known hypersensitivity reactions or allergy to investigational drugs or their excipients that contraindicates the subject's participation.
24. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial.
25. Patients under psychiatric care and patients admitted to a health or social institution.
26. Patients deprived of their liberty by judicial or administrative decision.
27. Patients under a legal protection measure or unable to express their consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A - Niraparib; Niraparib, 200 mg or 300 mg, daily dose	Drug: Niraparib; PARP Inhibitor
Experimental: Arm B - Niraparib + TSR-042 (Dostarlimab); Niraparib, 200 mg or 300 mg, daily dose TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter	Combination product: Niraparib + TSR-042 (Dostarlimab); Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
Active Comparator: Arm C - Chemotherapy drugs; Chemotherapies (Standard of care) For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days	Drug: Chemotherapy Drugs; Chemotherapies given in standard of care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response Rate (RR) at 4 months	RR is defined as the proportion of patients with a partial response or complete response 4 months after randomization	4 months after the last patient included
Overall survival (OS)	OS is the time from the date of the randomization until death due to any cause	1 year after the last patient included

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	PFS is the time from randomization to the date of event defined as the first documented progression (RECIST 1.1) or death due to any cause.	1 year after the last patient included
Time To Subsequent Treatment (TTST)	TTST is the time from the date of randomization to the earliest date of anti-cancer therapy start following study treatment discontinuation, or death by any cause in the absence of start of new anti-cancer therapy	1 year after the last patient included
Progression-Free Survival 2 (PFS2)	PFS2 is the time from the date of randomization to the second objective disease progression, or death from any cause, whichever occurs first.	1 year after the last patient included
Objective Response Rate (ORR)	ORR is the proportion of patients with a best response of Complete Response or Partial Response.	1 year after the last patient included
Adverse events	Assessed by CTCAE 5.0	1 year after the last patient included
Patient-reported outcomes (PROs)	Assessed with questionnaires to be completed by patient and collected frequently during the study	1 year after the last patient included

Collaborators and Investigators

• Sponsor: ARCAGY/ GINECO GROUP
• Collaborators: Tesaro, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2020
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): March 1, 2029

Study Registration Dates

• First Submitted: August 20, 2018
• First Submitted That Met QC Criteria: August 27, 2018
• First Posted (Actual): August 29, 2018

Study Record Updates

• Last Update Posted (Actual): June 1, 2026
• Last Update Submitted That Met QC Criteria: May 28, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Niraparib; Malignant mixed Mullerian tumors; Metastatic ovarian carcinosarcoma; Recurrent ovarian carcinosarcoma; Metastatic endometrial carcinosarcoma; Recurrent endometrial carcinosarcoma; TSR-042 (Dostarlimab)
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Genital Diseases, Female; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Gonadal Disorders; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Complex and Mixed; Ovarian Neoplasms; Carcinosarcoma; Mixed Tumor, Mullerian; Pharmacologic Actions; Chemical Actions and Uses; Therapeutic Uses; Antineoplastic Agents; niraparib; dostarlimab
• Other Study ID Numbers: ENGOT-en8

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No sharing plan

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No